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Review: Head and Neck Cancers 
Presentation and Evaluation of Patients with Epidermoid 
Head and Neck Cancers 
Michael S. Benninger, MD' 
Epidermoid cancer of the head and neck occurs most frequently in individuals wdh predisposing 
factors for neoplastic development. Primarily these include exposure to smoking and alcohol, 
although oiher predisposing factors may he present. Site-speciflc symptoms along wiih a history of 
predisposing environmental exposure can direct physicians to suspect head and neck cancer. 
Endoscopy and ancillary testing are peiformed for tumor staging and subsequent treatment planmng. 
(Henry Ford Hosp MedJ 1992;40:144-8) 
I n 1988, cancer was second only to heart disease in the United States as the leading cause of death, accounting for 461,563 
deaths, or 22.1 % of att deaths (1). Cancer of the head and neck, 
including skin, accounts for approximately 10% of atl cancers 
and greater than 5% of alt cancer deaths. Tables 1 through 3 list 
the incidence, mortality rate, and five-year survival of the more 
common head and neck cancers. According to the Surveillance, 
Epidemiology and End Results (SEER) Program of the National 
Cancer Institute, the incidence of oral cavity and oropharyngeal 
cancers is 82% higher in blacks than in whites, although there is 
no racial variance in cancer of the larynx. Site distribution also 
may vary with geography. In the East and Far East, oral cavity 
and oropharyngeal carcinomas account for almost one-half of 
all cancers (2). Squamous cell carcinoma accounts for most of 
head and neck cancer excluding that of the skin. 
Risk Factors for Head and Neck Cancer 
Risk factors for head and neck cancer depend on the site ofthe 
lesion. For most head and neck sites, there is a strong association 
between tobacco use and squamous cell carcinoma. Smoking 
has tong been known to be the primary risk factor (3) but recent 
evidence atso suggests a role of chewing tobacco in the develop-
ment of oral cavity and oropharyngeal cancers (4,5). Similarly, 
50% of all cancer in Bombay, India, is cancer of the buccal mu-
cosa which is associated with the custom of chewing pan (3), 
Smoking tobacco correlates best with subsequent carcinoma of 
the larynx. However, the American Academy of Otolaryngol-
ogy-Head and Neck Surgery is presently embarking on an ag-
gressive campaign against the chewing of tobacco. 
Drinking alcohol is also associated with the development of 
head and neck mucosal carcinomas. The actual mechanism re-
mains unproved. A direct topical effect has been hypothesized. 
especially in the oral cavity and oropharynx, although systemic 
effects of alcohol such as associated nutritional deficiencies, 
liver damage, or immunodeficiency may play a role (3). From 
an epidemiological standpoint, it is difficult to isolate alcohol 
from tobacco since most heavy users of alcohol are also smok-
ers. Studies controlled statistically for tobacco suggest that alco-
hol has an independent effect (6) and may correlate more closely 
with oral and oropharyngeal cancers than does smoking (7), All 
of these factors are dose-dependent. 
Conditions which cause chronic mucosal irritation, such as 
poor-fitting dentures, poor oral hygiene, and periodontal dis-
ease, also appearto be associated with mucosal cancers. Again, 
the difficulty of controlling for tobacco and alcohol and the 
prevalence of these conditions in the general population make 
isolation of these independent risk factors difficult (3). 
Leukoplakia, a term that means only "white patch," is fre-
quently found in an area of chronic inflammation, such as on the 
gingiva or buccal mucosa of those with dentures or on the palate 
of pipe smokers. In and of itself, leukoplakia has no pathologic 
significance. Reports of malignancy in a focus of leukoplakia 
range from 0.15% to 6%, depending on the site, with floor of 
mouth, base of tongue, and lip having a higher risk. Dysplasia is 
found in 8% to 24% of leukoplakia lesions (8) and approxi-
mately 3% have a frank carcinoma. Erythroplasia or "red patch" 
is a more significant process, with 50% having frank carcinoma 
while almost 90% have either carcinoma or carcinoma in situ. 
Plummer-Vincent syndrome with anemia can be associated 
with postcricoid carcinoma in women. 
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Site 
Table 1 
Incidence of New Head and Neck 
Cancer Cases by Site (1989)* 
Oral 
Lip 
Tongue 
Mouth 
Pharynx 
Subtotal 
Larynx 
Esophagus 
Thyroid 
Total 
New Cases 
Male Female 
3,800 
3,800 
7,100 
5,800 
20,500 
9,900 
6,900 
3,000 
40,300 
500 
2,000 
4,700 
2,500 
9,700 
2,300 
2,900 
8,000 
22,900 
Total 
4,300 
5,800 
11.800 
8,300 
30,200 
12,200 
9,800 
11,000 
63,200 
*Data relrieved from Cancer slaiislics, 1988. CA 1988:38:5-22. 
Site 
Table 2 
Predicted Mortality for Head and 
Neck Cancer Sites (1989)* 
Oral 
Lip 
Tongue 
Mouth 
Pharynx 
Subtotal 
Larynx 
Esophagus 
Thyroid 
Total 
Deaths 
Male Female 
100 
1,300 
1,700 
2,900 
6,000 
3,100 
6,600 
400 
16,100 
25 
700 
1,025 
1,300 
3,050 
700 
2,500 
700 
6,950 
Total 
125 
2,000 
2,725 
4,200 
9,050 
3,800 
9,100 
1,100 
23,050 
•Data retrieved from Cancer statistics, 1988. CA 1988:38:5-22. 
The lip is susceptible to carcinogens which affect the adjacent 
oral or facial epithelium. The major carcinogen to the lip is ac-
tinic radiation. Lip cancer is rare in blacks (1%) and tess com-
mon in women (10%) (3). Tobacco exposure is a known risk 
factor, and thermal irritation may play a role, as in clay pipe 
smokers. An association with lesions of herpes labialis has also 
been described (9). 
Nasopharyngeal carcinoma is a different disease than the 
other mucosal cancers of the head and neck. Histologically, 
these tumors are most frequently either nonkeratinizing squa-
mous cell carcinomas or lymphoepitheliomas. Different risk 
factors are implicated. The incidence of nasopharyngeal carci-
noma in the people of Kwang Tung Province of China is 25 
times higher than in whites, with a genetic component being 
suspected (3). Certain HLA haplotypes and familial clustering 
are observed, but tobacco exposure does not appear to be a ma-
jor risk factor in nasopharyngeal carcinoma. Occupational ex-
posure to nickel, wood dust, and solvents used in shoe making 
correlate with an increased incidence of nasopharyngeal carci-
noma. The role of the Epstein-Barr virus in the pathogenesis is 
disputed. 
A total of 90% of epidermoid carcinoma of the head and neck 
can be linked to environmental exposure. Glandular tumors, 
such as those of the salivary glands and thyroid, have been 
strongly linked to previous radiation therapy, especially to low-
dose therapy for benign diseases such as acne and adenoid or 
thymus hypertrophy (10). On the other hand, the genetic etiol-
ogy of medullary carcinoma of the thyroid has been demon-
strated in the multiple endocrine neoplasia (type 2A and 2B) 
syndromes. Immunosuppression increases the risk of develop-
ing neoplasms as do some nutritional deficiencies. The higher 
incidence of head and neck cancer in lower socioeconomic 
groups may be attributable to nutritional factors. 
Most head and neck cancers occur in the fifth through seventh 
decades of life but nasopharyngeal carcinoma often occurs in 
younger age groups. When squamous cell carcinoma occurs in 
younger age groups, it is often less cleariy associated with envi-
ronmental risk factors and seems to have a poorer prognosis 
(11). In such patients, a genetic predisposition has been postu-
lated. 
Table 3 
Predicted Five-Year Survival for Head and Neck Cancer* 
Site 5-Year Survival Rate 
Lip 91% 
Pharynx 32% 
Oral cavity/pharynx 54% (whites) 
31% (blacks) 
Larynx 66% (whites) 
55% (blacks) 
Esophagus 7% (whites) 
5% (blacks) 
Thyroid 93% (whites) 
95% (blacks) 
"Data retrieved from Cancer statistics, 1988. CA I98a;.'i8:5-22 
Symptoms of Head and Neck Cancer 
Symptoms of head and neck cancer are dependent on the site 
of the lesion. With the diversity of function of the aerodigestive 
tract, tumors at different sites produce a different constellation 
of symptoms. The universal symptoms of mucosal head and 
neck cancer are similar to those of other body sites—pain, 
bleeding, or a nonhealing sore or ulcer. Otalgia, a common gen-
eral complaint, can be referred pain from most areas ofthe upper 
airway. Cranial nerve V can refer pain to the ear from the oral 
cavity, mandible, temporomandibular joint, palate, and preau-
ricular or parotid regions. Pain can be referred from the tonsil, 
base of tongue, nasopharynx, eustachian tube, and pharynx via 
the petrosal ganglion and Jacobson's nerve (IX) and from the 
hypopharynx, larynx, and trachea via the nodose ganglion and 
Amold's nerve (X) (12). Although systemic symptoms are un-
usual in eariy head and neck cancer, they can be severe in more 
advanced disease. 
Metastasis to sites outside of the head and neck is unusual for 
head and neck cancer untess there is advanced disease. How-
ever, regional disease (neck metastasis) is common, with differ-
ent tumor sites in the head and neck having varied metastatic 
rates. Even within sites, nodal metastatic rates may vary by loca-
tion of the primary lesion. Neck metastases from a true vocal 
cord neoplasm are very low (less than 6%), while lymph node 
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Table 4 
Regional Lymph Node Metastasis for 
Various Head and Neck Cancer Sites 
Site Percentage 
Floor of mouth 39% 
Tonsil 61% 
Tongue 
Base 76% 
Oral 31% 
Palate 
Hard 15% 
Soft 37% 
Buccal mucosa 36% 
Alveolus 35% 
Epiglottis 42% 
FaLse vocal cord 29% 
True vocal cord 6% 
Subglottic 16% 
metastases from an epiglottic lesion occur in greater than 40% 
(13). In general, supragtottic cancers have a 33% metastatic rate 
while subglottic and transglottic lesions have rates of 19% and 
52%, respectively (14). Approximate rates of nodal metastases 
by site are noted in Table 4 (12-15). Primary neck tumors may 
be occult in as many as 38% of cases, depending on site. The lo-
cation of neck nodal metastases can help identify the primary 
site, but some patients may present with nodal metastases with-
out the primary site ever being discovered. Any persistent neck 
lymphadenopathy or mass should be investigated for possible 
metastatic disease. 
Laryngeal carcinomas often present in relatively early stages 
because of symptoms which occur early in the course of the dis-
ease. This is especially relevant for tme vocal cord lesions but 
less so for those on the false vocal cords. The cardinal symptoms 
of laryngeal cancer are hoarseness or a breathy voice. Persistent 
hoarseness, especially in a person with a history of smoking or 
alcohol abuse, should always be evaluated by indirect or direct 
laryngoscopy. Other symptoms of laryngeal cancer include 
vague, scratchy sensation; pain; dysphagia (difficulty swallow-
ing); odynophagia (pain with swallowing); hemoptysis; chronic 
cough; otalgia; and late symptoms associated with airway ob-
struction such as dyspnea or stridor. Halitosis can be present 
with extensive necrosing tumors. 
In contrast to the early clinical manifestations of true vocal 
cord tumors, cancer of the hypopharynx frequently produces 
symptoms only late in the course of the disease. Therefore, pa-
tients often present with more advanced disease, an associated 
higher metastatic rate, and higher treatment failure and mortal-
ity rates. Symptoms of hypopharyngeat cancers include dys-
phagia, odynophagia, pain, referred otalgia, or a neck mass. 
Hoarseness, which is often noted in early laryngeal cancers, is 
only present with large advanced hypopharyngeat cancers. 
Cancers ofthe oral cavity are frequentiy seen as a nonhealing 
ulcer or a mass. These can be painless unless irritated by chew-
ing. The pain becomes more constant as they enlarge and the 
area may bleed with manipulation. Edentulous patients find it 
difficult or painful to use their dentures and a history of not us-
ing dentures for a few weeks or months is not uncommon. With 
larger tumors, patients are often forced to softer diets because of 
discomfort associated with chewing or denture use. Halitosis is 
frequent with large tumors. A history of alcohol use is common 
while there may be a history of leukoplakia. 
Oropharyngeal tumors are often asymptomatic early, similar 
to those in the hypopharynx. Dysphagia or mild odynophagia 
can be present, worsening with more advanced disease. Pain and 
change in eating habits occur, possibly with associated halitosis 
or intermittent bleeding. Complaints of a chronic, gradually 
worsening "sore throat" are common. Such patients have fre-
quently been seen previously by physicians and diagnosed to 
have a viral upper respiratory tract infection or "strep throat." 
Patients with tumor of the tonsils or base of tongue often present 
with a neck mass, because more than 60% of such cancers me-
tastasize regionally (12). 
Nasopharyngeal tumors produce a more unusual symptom 
complex. Because nasal obstmction and posterior nasal drain-
age are common symptoms in the general population, these 
symptoms (which initially tend to be mild) are often ignored. 
The two most common presenting symptoms of nasopharyngeal 
carcinoma are serous otitis media from eustachian tube obstruc-
tion or a neck mass. Sixth and fifth cranial nerve involvement 
may produce the presenting symptoms. With more advanced 
disease, nasal obstmction worsens and epistaxis may occur. 
Salivary gland neoplasms are benign in a large proportion of 
patients, especially in the parotid gland where malignant neo-
plasms account for less than 20%, Malignant salivary gland tu-
mors produce few symptoms, A painless, fixed, gradually en-
larging mass is the most common complaint. Facial (VIII) nerve 
paralysis is highly suggestive of a malignancy and may be a 
poor prognostic sign. Skin ulceration, which occurs only with 
advanced tumors, is associated with poor survival rates. 
Symptoms of ear cancer are primarily otorrhea, conductive 
hearing loss, and pain. Ear fullness or pressure may be present, 
but bleeding from the extemal auditory canal may be the only 
symptom. Since chronic otitis media or cholesteatoma can re-
sutt in a similar constellation of symptoms, pain may be the only 
symptom leading the physician to suspect a malignancy. With 
more advanced disease, sensorineural deafness, vertigo, or fa-
cial nerve paralysis may occur. 
Evaluation of the Head and Neck Cancer Patient 
Evaluation of a patient with suspected carcinoma of the head 
and neck depends on a reliable history and physical examina-
tion. Risk factors for head and neck cancer, symptoms, and gen-
eral health information should be obtained. Physical examina-
tion should include an examination of the head and neck and 
skin and scalp, an otologic examination, and cranial nerve eval-
uation. Alt mucosal surfaces to the level of the cricoid and true 
vocal cords should be visualized. Frequentiy, the upper trachea 
can be seen between the vocal cords. A head mirror, good light-
ing with nasopharyngeal and laryngeal mirrors, tongue blades, 
and a nasal speculum can usually allow visualization of all mu-
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cosal areas. For the patient who cannot be adequately examined 
or for better visualization, a flexible nasopharyngotaryngoscope 
can be easily used in the office with minimum patient discom-
fort. Careful palpation of the salivary glands, neck, laryngeal 
cartilages, and thyroid should be achieved along with palpation 
ofthe floor of mouth, palate, tongue, and tonsils. 
A chest x-ray should be obtained in all patients suspected of 
having head and neck cancer since metastatic pulmonary dis-
ease may occur. Moreover, chronic pulmonary disease is com-
mon in this population in whom a long history of tobacco use is 
frequent. Biopsies of all suspicious lesions should be obtained 
either in the office using local anesthesia or in the operating 
room if the site is inaccessible. Fine-needle aspiration has been 
found to be an excellent, minimally invasive procedure for the 
diagnosis of thyroid, salivary gland, and neck masses (16). 
Open surgical lymph node biopsy for evaluation without 
planned concurrent treatment of the primary site is controver-
sial. Risk of potentially lower survival rates has been reported in 
such patients, compared to those diagnosed and treated for the 
primary and neck metastases simultaneously (17). If possible, 
open biopsy should be performed at the time of primary treat-
ment. 
Direct pharyngolaryngoscopy may be performed in the oper-
ating room setting along with bronchoscopy and esophagos-
copy to mte out simultaneous primary neoplasms of the upper 
aerodigestive tract (18,19). Systemic evaluation other than 
physical examination, basic laboratory studies, chest x-ray, and 
possible endoscopy is usually not indicated because distant 
metastatic disease is not likely. 
Imaging procedures for head and neck cancers have had a 
limited role in the diagnostic workup. Although not generally 
performed, computed tomography or magnetic resonance imag-
ing has been advocated to assist in the staging of head and neck 
neoplasms as well as in treatment planning (20-22). Until the 
value of such studies is better known, a thorough history and 
physical examination with endoscopy is sufficient to evaluate, 
diagnose, and stage most head and neck malignancies. Careful 
mapping of tumor location, size, and characteristics is essential. 
With these studies in mind, guidelines for referral of patients 
with possible head and neck cancers can be made. Any individ-
ual with persistent hoarseness, hemoptysis, a painful or unheal-
ing sore in the head or neck, persistent dysphagia, or a neck mass 
(particularly in individuals with predisposing factors for head 
and neck tumors) should be referred to an otolaryngologist or 
other head and neck specialist. 
Staging of Head and Neck Cancer 
In the United States, staging of head and neck cancer is based 
on the TNM classification of the American Joint Committee on 
Cancer Staging and End Results Reporting from 1988 (23). This 
system relies on T (primary site), N (nodal), and M (metastatic) 
clinical assessment to establish tumor stage (Table 5). Although 
the staging categories are utilized to evaluate demographic data 
and treatment response, most tumors are better evaluated for 
treatment options and survival by careful assessment of the TN 
status of the individual sites. 
Table 5 
Staging of Head and Neck Carcinoma 
Stage I T,N„M„ 
Stage II T2N„M„ 
Stage III T3NoM„orT,_3N,M„ 
Stage IV T^Ng |M„ or T| ^N, ,M„ or any T, any N, M, 
Treatment of Head and Neck Cancer 
Treatment of head and neck cancer is evolving, as is that of 
most cancer. The standard of therapy is surgical treatment, radi-
ation therapy, or a combination of radiation therapy and surgical 
treatment. The choice of treatment will depend on the site and 
stage with concems for morbidity and subsequent rehabilitation 
being an integral part of treatment planning. Small tumors in 
most sites are generally welt managed by either surgery or radia-
tion therapy. Large tumors frequently require combined therapy 
(surgery and radiation), often with good results (24,25). Treat-
ment planning must aim to maintain satisfactory posttreatment 
airway, swallowing, and speech function. Although slightiy tess 
important, the cosmetic result should be considered in the evalu-
ation. 
Chemotherapy has not been proved to alter survival of pa-
tients with head and neck squamous cell carcinomas, either 
when used alone or in combination with surgery or radiation. 
However, increasing evidence suggests good response rates and 
possible prolonged survival (26-28), At present, chemotherapy 
is generally included in treatment only under protocol studies or 
in unresectable disease but holds much promise for the future. 
Biologic modifiers and immunotherapy are being investigated 
and in the future may well be used in managing head and neck 
cancer (29,30). 
Treatment planning is best accomplished by a Head and Neck 
Oncology Board with input from otolaryngologists, other head 
and neck surgeons, radiation oncologists, medical oncologists, 
speech and swallowing therapists, social workers, head and neck 
nurse-clinicians, pathologists, radiologists, and other health 
care professionals. This interdisciplinary expertise is recom-
mended to best evaluate the needs of the head and neck cancer 
patients and their families. Close attention to posttherapy func-
tion and occupational rehabilitation is essential. Fewer than 
50% of head and neck cancer patients retum to the competitive 
labor market and more than 50% of "blue collar" head and neck 
cancer patients indicate a need for mental health counseling. In 
comparison, only 20% of similar breast and colon-rectal cancer 
patients indicate a need for such counseling (31). 
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